Annual CFF
$11.40 M
-$114.57 M-90.95%
December 31, 2024
Summary
- As of March 13, 2025, INZY annual cash flow from financing activities is $11.40 million, with the most recent change of -$114.57 million (-90.95%) on December 31, 2024.
- During the last 3 years, INZY annual CFF has risen by +$10.79 million (+1771.59%).
- INZY annual CFF is now -92.39% below its all-time high of $149.81 million, reached on December 31, 2020.
Performance
INZY Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$258.00 K
-$10.27 M-97.55%
December 31, 2024
Summary
- As of March 13, 2025, INZY quarterly cash flow from financing activities is $258.00 thousand, with the most recent change of -$10.27 million (-97.55%) on December 31, 2024.
- Over the past year, INZY quarterly CFF has dropped by -$10.27 million (-97.55%).
- INZY quarterly CFF is now -99.78% below its all-time high of $118.86 million, reached on September 30, 2020.
Performance
INZY Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$11.40 M
-$12.26 M-51.82%
December 31, 2024
Summary
- As of March 13, 2025, INZY TTM cash flow from financing activities is $11.40 million, with the most recent change of -$12.26 million (-51.82%) on December 31, 2024.
- Over the past year, INZY TTM CFF has dropped by -$12.26 million (-51.82%).
- INZY TTM CFF is now -92.44% below its all-time high of $150.81 million, reached on September 30, 2020.
Performance
INZY TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
INZY Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -91.0% | -97.5% | -51.8% |
| 3 y3 years | +1771.6% | +100.0% | -84.3% |
| 5 y5 years | -50.4% | +100.0% | -84.3% |
INZY Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -91.0% | +1771.6% | -99.6% | -100.0% | -91.0% | +1799.7% |
| 5 y | 5-year | -92.4% | +1771.6% | -99.8% | +126.2% | -92.4% | +3037.6% |
| alltime | all time | -92.4% | +1771.6% | -99.8% | +126.2% | -92.4% | +3037.6% |
Inozyme Pharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $11.40 M(-91.0%) | $258.00 K(-97.5%) | $11.40 M(-51.8%) |
| Sep 2024 | - | $10.52 M(+2197.6%) | $23.66 M(-71.4%) |
| Jun 2024 | - | $458.00 K(+188.1%) | $82.85 M(-21.9%) |
| Mar 2024 | - | $159.00 K(-98.7%) | $106.03 M(-15.8%) |
| Dec 2023 | $125.97 M(+73.1%) | $12.52 M(-82.0%) | $125.97 M(+11.0%) |
| Sep 2023 | - | $69.72 M(+194.9%) | $113.45 M(+136.6%) |
| Jun 2023 | - | $23.64 M(+17.6%) | $47.95 M(-48.2%) |
| Mar 2023 | - | $20.10 M(>+9900.0%) | $92.64 M(+27.3%) |
| Dec 2022 | $72.79 M(>+9900.0%) | $0.00(-100.0%) | $72.79 M(-0.0%) |
| Sep 2022 | - | $4.21 M(-93.8%) | $72.80 M(+5.8%) |
| Jun 2022 | - | $68.33 M(>+9900.0%) | $68.82 M(>+9900.0%) |
| Mar 2022 | - | $240.00 K(+2081.8%) | $600.00 K(-1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $609.00 K(-99.6%) | $11.00 K(-95.4%) | $609.00 K(-257.0%) |
| Sep 2021 | - | $237.00 K(+111.6%) | -$388.00 K(-100.3%) |
| Jun 2021 | - | $112.00 K(-55.0%) | $118.24 M(-21.2%) |
| Mar 2021 | - | $249.00 K(-125.3%) | $150.06 M(+0.2%) |
| Dec 2020 | $149.81 M(+552.2%) | -$986.00 K(-100.8%) | $149.81 M(-0.7%) |
| Sep 2020 | - | $118.86 M(+272.2%) | $150.81 M(+371.6%) |
| Jun 2020 | - | $31.93 M(>+9900.0%) | $31.98 M(>+9900.0%) |
| Mar 2020 | - | $5000.00(-44.4%) | $43.00 K(-99.8%) |
| Dec 2019 | $22.97 M(-28.1%) | $9000.00(-69.0%) | $22.97 M(+0.0%) |
| Sep 2019 | - | $29.00 K(>+9900.0%) | $22.96 M(+0.1%) |
| Jun 2019 | - | $0.00(-100.0%) | $22.93 M(0.0%) |
| Mar 2019 | - | $22.93 M | $22.93 M |
| Dec 2018 | $31.95 M | - | - |
FAQ
- What is Inozyme Pharma annual cash flow from financing activities?
- What is the all time high annual CFF for Inozyme Pharma?
- What is Inozyme Pharma annual CFF year-on-year change?
- What is Inozyme Pharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Inozyme Pharma?
- What is Inozyme Pharma quarterly CFF year-on-year change?
- What is Inozyme Pharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for Inozyme Pharma?
- What is Inozyme Pharma TTM CFF year-on-year change?
What is Inozyme Pharma annual cash flow from financing activities?
The current annual CFF of INZY is $11.40 M
What is the all time high annual CFF for Inozyme Pharma?
Inozyme Pharma all-time high annual cash flow from financing activities is $149.81 M
What is Inozyme Pharma annual CFF year-on-year change?
Over the past year, INZY annual cash flow from financing activities has changed by -$114.57 M (-90.95%)
What is Inozyme Pharma quarterly cash flow from financing activities?
The current quarterly CFF of INZY is $258.00 K
What is the all time high quarterly CFF for Inozyme Pharma?
Inozyme Pharma all-time high quarterly cash flow from financing activities is $118.86 M
What is Inozyme Pharma quarterly CFF year-on-year change?
Over the past year, INZY quarterly cash flow from financing activities has changed by -$10.27 M (-97.55%)
What is Inozyme Pharma TTM cash flow from financing activities?
The current TTM CFF of INZY is $11.40 M
What is the all time high TTM CFF for Inozyme Pharma?
Inozyme Pharma all-time high TTM cash flow from financing activities is $150.81 M
What is Inozyme Pharma TTM CFF year-on-year change?
Over the past year, INZY TTM cash flow from financing activities has changed by -$12.26 M (-51.82%)